SQ tree sublingual immunotherapy tablet for treating moderate to severe allergic rhinitis and/or conjunctivitis in children and adolescents

The SQ tree sublingual immunotherapy (SLIT)–tablet is currently in clinical development for the treatment of tree pollen–induced allergic rhinitis (AR) and/or conjunctivitis, a highly prevalent respiratory condition. Globally, it is estimated that more than 10 million children have uncontrolled respiratory allergies. Pollen allergies are a major cause of allergic rhinoconjunctivitis, and birch pollen is one of the most common seasonal allergies. AR can impair quality of life, sleep, and work/school performance amongst those affected. Allergen avoidance, although representing optimal management for allergic diseases, is not often feasible and symptomatic treatment with anti-allergic medication may only be partially effective. The SQ SLIT tablet will offer a long-term treatment option for which there are currently few options.